Aquestive Therapeutics is a drug manufacturers-specialty & generic business based in the US. Aquestive Therapeutics shares (AQST) are listed on the NASDAQ and all prices are listed in US Dollars. Aquestive Therapeutics employs 157 staff and has a trailing 12-month revenue of around $48.1 million.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $0.88 |
|---|---|
| 52-week range | $0.62 - $3.19 |
| 50-day moving average | $0.92 |
| 200-day moving average | $1.06 |
| Wall St. target price | $5.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.75 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.8799 from 2023-02-01
| 1 week (2023-01-27) | -0.76% |
|---|---|
| 1 month (2023-01-03) | -2.22% |
| 3 months (2022-11-03) | 2.05% |
| 6 months (2022-08-03) | 5.00% |
| 1 year (2022-02-01) | -69.02% |
|---|---|
| 2 years (2021-02-03) | -84.43% |
| 3 years (2020-02-03) | 3.95 |
| 5 years (2018-01-30) | N/A |
| Revenue TTM | $48.1 million |
|---|---|
| Gross profit TTM | $35.8 million |
| Return on assets TTM | -45.91% |
| Return on equity TTM | 0% |
| Profit margin | -147.69% |
| Book value | $-2.00 |
| Market capitalisation | $48.2 million |
TTM: trailing 12 months
We're not expecting Aquestive Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Aquestive Therapeutics's shares have ranged in value from as little as $0.618 up to $3.19. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aquestive Therapeutics's is 2.725. This would suggest that Aquestive Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Aquestive Therapeutics, Inc. , a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.